Observation of the Effect of Sintilimab Combined with Pemetrexed in the Clinical Treatment of Advanced Non-small Cell Lung Cancer Patients with Negative Driver Genes
Wen Jingjing
Chen Jinhong
Chen Yaoqiang
Abstract：Objective:To explore the letter dilip single combined therapy with pemetrexed drive rust resistance genes in advanced non-small cell lung cancer(NSCLC)patients with clinical effect.Methods:84 patients with advanced NSCLC admitted to Xinmi Hospital of Traditional Chinese Medicine from March 2021 to October 2023 were selected,and divided into two groups according to the random number table method.40 patients of control group were treated with pemetrexed and cisplatin chemotherapy,and 44 patients of the observation group were treated with sintilimab.The clinical efficacy,serum tumor marker level,immune function,quality of life,adverse reactions were compared.Results:ORR and DCR in the observation group were higher than those in the control group,and the differences were statistically significant(χ2=4.635,5.295;P<0.05).After treatment,CEA,CA125,CA199 and CYFRA21-1 in observation group were lower than those in observation group,with statistically significant difference(t=8.419,21.002,5.555,10.069;P<0.05).After treatment,CD3+and CD4+in observation group were all higher,and CD8+was lower than observation group,with statistically significant difference(t=10.644,3.550,6.837;P<0.05).After treatment,the SF-36 scores in the observation group were higher than those in the control group,with statistically significant difference(t=7.302,9.582,7.242,6.659,5.058;P<0.05).There was no significant difference in the adverse reaction rate between the two groups(χ2=0.161,P>0.05).Conclusion:Treatment with sindilizumab plus pemetrexed can effectively reduce the level of serum tumor markers,promote immune function and improve quality of life in patients with advanced NSCLC with negative driver genes,and it is safe and reliable.
Keywords：Driver gene negativeAdvanced non-small cell lung cancerSintilimabPemetrexedSerum tumor markersImmune functionQuality of life
Publication Date：2025-05-10
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1090-1093 )